Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- An ...
Tenosynovial giant cell tumors are not malignant but can impact patients’ quality of life, as one expert explained. There are not many patients with tenosynovial giant cell tumors, or TGCTs, with one ...
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...
Systemic therapy and active surveillance can be viable options for patients with TGCT, as one expert explained. Sydney Stern has undergone six surgeries for TGCT, or tenosynovial giant cell tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback